BIB

ProShares Ultra NASDAQ Biotechnology
*Unless otherwise stated, data provided by FactSet.

BIB Fund Description

BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.

BIB Factset Analytics Insight

BIB is a popular leveraged play on the NASDAQ Biotechnology Index, which is also tracked in unlevered form by the hugely popular iShares' IBB, and is heavily focused on Nasdaq's biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through swap agreements with multiple counterparties, and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading, since compounding effects over the long term could create vast differences from expected returns—for good or for ill. BIB has been around since April 2010 and is well established, with healthy assets, which puts any closure risk to rest. Yet traders should be cautious: daily volume is strong, but spreads and volatility can be high, likely reflecting the volatile underlying assets.

BIB MSCI ESG Analytics Insight

ProShares Ultra NASDAQ Biotechnology has an MSCI ESG Fund Rating of BB based on a score of 4.09 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ProShares Ultra NASDAQ Biotechnology ranks in the 22nd percentile within its peer group and in the 21st percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

BIB Charts And Performance

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 09/11/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
BIB -1.87% 2.61% 12.21% -27.10% 1.48% -1.90% --
BIB (NAV) -1.75% 2.67% 11.41% -27.15% 1.52% -1.92% --
NASDAQ Biotechnology Index -0.55% 2.22% 8.55% -10.46% 4.63% 3.30% --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

BIB Summary Data

ProShares
04/08/10
Open-Ended Fund
0.95%
$187.37M
0.11%

BIB Portfolio Data

0.00%
09/25/19

BIB Index Data

Market Cap
NASDAQ - Listed
N/A

BIB Fund Structure

Yes
No
No Policy
N/A
N/A
High
2
Daily

BIB Tax Exposures

20.00% / 39.60%
--
No
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

BIB Factset Analytics Block Liquidity

As of 09/13/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BIB. BIB is rated a N/A out of 5.

BIB Tradability

112,577
$5.31M
106,119
$5.02M
0.11%
$0.05
-0.02%
0.57% / -0.75%
None
0.00%
50,000
2.12
0.01%
--
2,850
$47.25
N/A

BIB MSCI ESG Ratings

BB
4.09 / 10
21.11
21.86
0.14%
30.32%
23.59